Related Experiment Videos
Therapeutic standards in Alzheimer disease
1Baylor College of Medicine, Department of Neurology, Houston, Texas 77030, USA. rdoody@bcm.tmc.edu
Alzheimer Disease and Associated Disorders
|January 6, 2000
Summary
Donepezil offers symptomatic relief for Alzheimer disease (AD), improving cognition and daily function. Vitamin E may also slow AD progression, potentially joining donepezil as a standard therapy.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Alzheimer disease (AD) is a progressive neurodegenerative disorder.
- Current treatments primarily focus on symptomatic relief and slowing disease progression.
- Established therapies include symptomatic treatments like donepezil.
Purpose of the Study:
- To evaluate the efficacy and safety of donepezil for mild-to-moderate Alzheimer disease (AD).
- To assess the potential of Vitamin E as a therapy to slow the progression of AD.
- To compare the therapeutic roles of donepezil and Vitamin E in AD management.
Main Methods:
- Phase III clinical trials were conducted to assess donepezil's effects.
- Data analysis focused on cognitive function, global status, and activities of daily living.
- A large-scale clinical trial investigated the benefits and safety of Vitamin E over a two-year period.
Main Results:
- Donepezil demonstrated significant improvements in cognition, global function, and daily living activities.
- Donepezil exhibited a favorable safety profile with mild, transient adverse events.
- Vitamin E showed potential benefits and safety, suggesting it could be a standard AD therapy alongside donepezil.
Conclusions:
- Donepezil is an effective and well-tolerated symptomatic treatment for mild-to-moderate Alzheimer disease.
- Vitamin E shows promise in slowing AD progression and may be considered a standard therapy.
- Both donepezil and Vitamin E represent important therapeutic options for managing Alzheimer disease.